Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
2.63 USD +5.20% Intraday chart for VYNE Therapeutics Inc. +13.36% +12.88%
04-04 Transcript : VYNE Therapeutics Inc. - Special Call
02-29 VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on VYNE Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

54c5371ccd9.CkTz6TkId_oqxrYwZoz3H6se3D5rFruoo_b12D7xn48.JwasrFFAAqpljYd3UMXDeZJ5iFxeRd345q6EoQqAx-U6dr2QbF49q0eO1Q~61c4b7834a24a28fbbafc3478b9e097d

Analyst Recommendations on VYNE Therapeutics Inc.

Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating MT
HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating MT
HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target MT
VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating MT
VYNE THERAPEUTICS : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating MT
VYNE THERAPEUTICS : Barclays Adjusts Price Target for VYNE Therapeutics to $15 From $12, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.5 USD
Average target price
5.583 USD
Spread / Average Target
+123.33%
High Price Target
6 USD
Spread / Highest target
+140.00%
Low Price Target
5 USD
Spread / Lowest Target
+100.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering VYNE Therapeutics Inc.

Cantor Fitzgerald
HC Wainwright
Northland Securities

Ratings for VYNE Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. Consensus VYNE Therapeutics Inc.